Neurocognitive DisordersHealthy VolunteersPersonality & Trait FactorsLSDPsilocybin

Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences

This double-blind, placebo-controlled study (n=20) with psilocybin (10, 20, 30mg/70kg) and DMX (400mg/70kg) finds very similar subjective effects between the two drugs. The visual, mystical, and insightful effects were more pronounced with psilocybin, disembodiment with DMX.

Authors

  • Matthew Johnson
  • Theresa Carbonaro

Published

Psychopharmacology
individual Study

Abstract

Rationale

Although psilocybin and dextromethorphan (DXM) are hallucinogens, they have different receptor mechanisms of action and have not been directly compared.

Objective

This study compared subjective, behavioral, and physiological effects of psilocybin and dextromethorphan under conditions that minimized expectancy effects.

Methods

Single, acute oral doses of psilocybin (10, 20, 30 mg/70 kg), DXM (400 mg/70 kg), and placebo were administered under double-blind conditions to 20 healthy participants with histories of hallucinogen use. Instructions to participants and staff minimized expectancy effects. Various subjective, behavioral, and physiological effects were assessed after drug administration.

Results

High doses of both drugs produced similar increases in participant ratings of peak overall drug effect strength, with similar times to maximal effect and time-course. Psilocybin produced orderly dose-related increases on most participants rated subjective measures previously shown sensitive to hallucinogens. DXM produced increases on most of these same measures. However, the high dose of psilocybin produced significantly greater and more diverse visual effects than DXM including greater movement and more frequent, brighter, distinctive, and complex (including textured and kaleidoscopic) images and visions. Compared to DXM, psilocybin also produced significantly greater mystical-type and psychologically insightful experiences and greater absorption in music. In contrast, DXM produced larger effects than psilocybin on measures of disembodiment, nausea/emesis, and light-headedness. Both drugs increased systolic blood pressure, heart rate, and pupil dilation and decreased psychomotor performance and balance.

Conclusions

Psilocybin and DXM produced similar profiles of subjective experiences, with psilocybin producing relatively greater visual, mystical-type, insightful, and musical experiences, and DXM producing greater disembodiment.

Available with Blossom Pro

Research Summary of 'Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences'

Introduction

Classic serotonergic psychedelics (serotonin 2A receptor agonists) such as psilocybin and dissociative hallucinogens (NMDA receptor antagonists) such as dextromethorphan (DXM) differ in primary pharmacology but may produce overlapping subjective effects. Earlier blinded work had found that a high oral dose of DXM (400 mg/70 kg) produced subjective profiles similar to those of classic hallucinogens on a range of self-report measures, yet relatively little work has directly compared the acute neurocognitive effects of classic and dissociative hallucinogens in the same participants. Barrett and colleagues designed a double-blind, placebo-controlled, within-subjects complete-crossover study to compare dose-dependent neurocognitive effects of oral psilocybin (10, 20, and 30 mg/70 kg) with a single high oral dose of DXM (400 mg/70 kg). The investigators tested two primary hypotheses: that DXM would produce greater impairments than psilocybin on psychomotor, memory, and executive-function tasks, and that psilocybin would produce greater effects on a visual-perception task given its known visual network effects.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (31)

Papers cited by this study that are also in Blossom

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)

Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults

Brown, R. T., Nicholas, C. R., Cozzi, N. V. et al. · Clinical Pharmacokinetics (2017)

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)

The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs

Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)

1174 cited
Neural correlates of the LSD experience revealed by multimodal neuroimaging

Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)

Show all 31 references
Potential Therapeutic Effects of Psilocybin

Johnson, M. W., Griffiths, R. R. · Neurotherapeutics (2017)

Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)

Long-term follow-up of psilocybin-facilitated smoking cessation

Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)

562 cited
LSD modulates music-induced imagery via changes in parahippocampal connectivity

Kaelen, M., Roseman, L., Kahan, J. et al. · European Neuropsychopharmacology (2016)

Serotonergic Hallucinogen-Induced Visual Perceptual Alterations

Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)

The 5-HT2A/1A Agonist Psilocybin Disrupts Modal Object Completion Associated with Visual Hallucinations

Kometer, M., Cahn, B. R., Andel, D. et al. · Biological Psychiatry (2011)

74 cited
Psychedelics

Nichols, D. E. · Pharmacological Reviews (2016)

The pharmacology of psilocybin

Passie, T., Seifert, J., Schneider, U. et al. · Addiction Biology (2002)

Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers

Quednow, B. B., Kometer, M., Geyer, M. A. et al. · Neuropsychopharmacology (2011)

LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion

Roseman, L., Sereno, M. I., Leech, R. et al. · Human Brain Mapping (2016)

Acute effects of lysergic acid diethylamide in healthy subjects

Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)

Acute LSD effects on response inhibition neural networks

Schmidt, A., Müller, F., Lenz, C. et al. · Psychological Medicine (2017)

Psilocybin - Summary of knowledge and new perspectives

Tylš, F., Páleníček, T., Horacek, J. · European Neuropsychopharmacology (2013)

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)

Cited By (43)

Papers in Blossom that reference this study

Roland R. Griffiths, psychopharmacology pioneer: Abuse liability, alcohol, nicotine, caffeine, benzodiazepines, and psychedelics

Henningfield, J. E., Barrett, F. S., Evans, S. M. et al. · Journal of Psychopharmacology (2026)

1 cited
Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial

Meikle, S., Carter, O., Liknaitzky, P. et al. · Therapeutic Advances in Psychopharmacology (2025)

Insights on Psychedelics: A Systematic Review of Therapeutic Effects

Kugel, J., Laukkonen, R., Yaden, D. B. et al. · Neuroscience and Biobehavioral Reviews (2025)

Safety pharmacology of acute psilocybin administration in healthy participants

Straumann, I., Holze, F., Becker, A. M. et al. · Neuroscience Applied (2024)

15 cited
Show all 43 papers
Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics

Jaster, A. M., González-Maeso, J. · Molecular Psychiatry (2023)

History repeating: guidelines to address common problems in psychedelic science

Van Elk, M., Fried, E. I. · Therapeutic Advances in Psychopharmacology (2023)

94 cited
Assessment of the acute effects of 2C-B vs psilocybin on subjective experience, mood and cognition

Mallaroni, P., Mason, N. L., Reckweg, J. T. et al. · Clinical Pharmacology and Therapeutics (2023)

39 cited
Effect of LSD and music on the time-varying brain dynamics

Adamska, I., Finc, K. · Psychopharmacology (2023)

7 cited
2 cited
The Altered States Database: Psychometric data from a systematic literature review

Prugger, J., Derdiyok, E., Dinkelacker, J. et al. · Scientific Data (2022)

Pharmacological, Neural, and Psychological Mechanisms underlying Psychedelics: A Critical Review

van Elk, M., Yaden, D. B. · Neuroscience and Biobehavioral Reviews (2022)

Group VR experiences can produce ego attenuation and connectedness comparable to psychedelics

Glowacki, D. R., Wonnacott, M. D., Freire, R. et al. · Scientific Reports (2022)

31 cited
Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms

Kopra, E., Ferris, J. A., Winstock, A. R. et al. · Journal of Psychopharmacology (2022)

Predictors and potentiators of psychedelic-occasioned mystical experiences

Gandy, S. · Journal of Psychedelic Studies (2022)

The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)

Reckweg, J., Uthaug, M. V., Szabo, A. et al. · Journal of Neurochemistry (2022)

Human behavioral pharmacology of psychedelics

Strickland, J. C., Johnson, M. W. · Advances in Pharmacology (2022)

5 cited
Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective

Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)

Models of psychedelic drug action: modulation of cortical-subcortical circuits

Doss, M. K., Madden, M. B., Gaddis, A. et al. · Brain (2021)

Great Expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials

Aday, J. S., Heifets, B. D., Pratscher, S. D. et al. · Psychopharmacology (2021)

Dose-response relationships of psilocybin-induced subjective experiences in humans

Hirschfeld, T., Schmidt, T. T. · Journal of Psychopharmacology (2021)

Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches

Garcia-Romeu, A., Barrett, F. S., Carbonaro, T. M. et al. · Journal of Psychopharmacology (2021)

Psychedelics and Psychotherapy

Nayak, S., Johnson, M. W. · Pharmacopsychiatry (2020)

Psilocybin induces time-dependent changes in global functional connectivity: Psi-induced changes in brain connectivity

Preller, K. H., Burt, J. B., Adkinson, B. et al. · Biological Psychiatry (2020)

Isness: Using Multi-Person VR to Design Peak Mystical Type Experiences Comparable to Psychedelics

Glowacki, D. R., Wonnacott, M. D., Freire, R. et al. · Association for Computing Machinery (2020)

32 cited
Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications

O'callaghan, C., Hubik, D. J., Psychiatry, M. et al. · Journal of Music Therapy (2020)

Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience

Lewis, C. R., Preller, K. H., Braden, B. B. et al. · Biomedicines (2020)

24 cited
Emotions and brain function are altered up to one month after a single high dose of psilocybin

Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)

REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics

Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)

143 cited
Psychedelics and music: neuroscience and therapeutic implications

Barrett, F. S., Preller, K. H., Kaelen, M. · International Review of Psychiatry (2018)

The entropic brain - revisited

Carhart-Harris, R. L. · Neuropharmacology (2018)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.